GB201417018D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201417018D0
GB201417018D0 GBGB1417018.7A GB201417018A GB201417018D0 GB 201417018 D0 GB201417018 D0 GB 201417018D0 GB 201417018 A GB201417018 A GB 201417018A GB 201417018 D0 GB201417018 D0 GB 201417018D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417018.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1417018.7A priority Critical patent/GB201417018D0/en
Publication of GB201417018D0 publication Critical patent/GB201417018D0/en
Priority to KR1020177007735A priority patent/KR20170054413A/ko
Priority to CA2962319A priority patent/CA2962319A1/en
Priority to JP2017516386A priority patent/JP6672276B2/ja
Priority to RU2017114352A priority patent/RU2017114352A/ru
Priority to US15/514,414 priority patent/US10004724B2/en
Priority to BR112017006240A priority patent/BR112017006240A2/pt
Priority to CN201580052202.3A priority patent/CN107074850A/zh
Priority to AU2015320874A priority patent/AU2015320874A1/en
Priority to PCT/EP2015/071798 priority patent/WO2016046241A1/en
Priority to EP15767479.7A priority patent/EP3197895B1/en
Priority to ES15767479T priority patent/ES2796235T3/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1417018.7A 2014-09-26 2014-09-26 Novel compounds Ceased GB201417018D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1417018.7A GB201417018D0 (en) 2014-09-26 2014-09-26 Novel compounds
ES15767479T ES2796235T3 (es) 2014-09-26 2015-09-22 Derivados de naftiridina como antagonistas de la integrina alfa V beta 6 para el tratamiento de enfermedades fibróticas
RU2017114352A RU2017114352A (ru) 2014-09-26 2015-09-22 АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
CA2962319A CA2962319A1 (en) 2014-09-26 2015-09-22 Novel compounds
JP2017516386A JP6672276B2 (ja) 2014-09-26 2015-09-22 新規化合物
KR1020177007735A KR20170054413A (ko) 2014-09-26 2015-09-22 신규한 화합물
US15/514,414 US10004724B2 (en) 2014-09-26 2015-09-22 Compounds alpha v beta 6 integrin antagonists
BR112017006240A BR112017006240A2 (pt) 2014-09-26 2015-09-22 novos compostos
CN201580052202.3A CN107074850A (zh) 2014-09-26 2015-09-22 新化合物
AU2015320874A AU2015320874A1 (en) 2014-09-26 2015-09-22 Novel compounds
PCT/EP2015/071798 WO2016046241A1 (en) 2014-09-26 2015-09-22 Novel compounds
EP15767479.7A EP3197895B1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of fibrotic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417018.7A GB201417018D0 (en) 2014-09-26 2014-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
GB201417018D0 true GB201417018D0 (en) 2014-11-12

Family

ID=51901174

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417018.7A Ceased GB201417018D0 (en) 2014-09-26 2014-09-26 Novel compounds

Country Status (12)

Country Link
US (1) US10004724B2 (cg-RX-API-DMAC10.html)
EP (1) EP3197895B1 (cg-RX-API-DMAC10.html)
JP (1) JP6672276B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170054413A (cg-RX-API-DMAC10.html)
CN (1) CN107074850A (cg-RX-API-DMAC10.html)
AU (1) AU2015320874A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017006240A2 (cg-RX-API-DMAC10.html)
CA (1) CA2962319A1 (cg-RX-API-DMAC10.html)
ES (1) ES2796235T3 (cg-RX-API-DMAC10.html)
GB (1) GB201417018D0 (cg-RX-API-DMAC10.html)
RU (1) RU2017114352A (cg-RX-API-DMAC10.html)
WO (1) WO2016046241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
EP3538528B1 (en) 2016-11-08 2020-12-23 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
PT3538525T (pt) 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
AU2017359028A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
JP7291696B2 (ja) 2017-11-07 2023-06-15 ブリストル-マイヤーズ スクイブ カンパニー アルファvインテグリン阻害剤としてのピロロピラジン誘導体
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047425A4 (en) * 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1229910A4 (en) 1999-10-04 2003-10-01 Merck & Co Inc integrin
YU32502A (sh) 1999-11-08 2004-12-31 Merck & Co.Inc. Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
AU7793501A (en) 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU2002246757B2 (en) 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
MX2009010050A (es) 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
AU2015320874A1 (en) 2017-03-09
WO2016046241A1 (en) 2016-03-31
EP3197895A1 (en) 2017-08-02
BR112017006240A2 (pt) 2017-12-12
CN107074850A (zh) 2017-08-18
JP2017528506A (ja) 2017-09-28
US20170290818A1 (en) 2017-10-12
RU2017114352A (ru) 2018-10-26
JP6672276B2 (ja) 2020-03-25
ES2796235T3 (es) 2020-11-26
EP3197895B1 (en) 2020-03-11
CA2962319A1 (en) 2016-03-31
KR20170054413A (ko) 2017-05-17
US10004724B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
IL250345A0 (en) new compounds
IL250592A0 (en) new compounds
SI3134402T1 (sl) 4-amino-imidazokinolinske spojine
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201417011D0 (en) Novel compounds
GB201417094D0 (en) Novel compounds
GB201405991D0 (en) Novel compounds
GB201410430D0 (en) Compounds
GB201402431D0 (en) Compounds
AP2016009432A0 (en) Novel compounds
GB201411236D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201404002D0 (en) Novel compounds
GB201406591D0 (en) Compounds
GB201406956D0 (en) Compounds
GB201404987D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
IL248983A0 (en) new compounds
GB201419102D0 (en) Novel compounds
GB201407695D0 (en) Compounds
PL3154977T3 (pl) Nowe związki
GB201405361D0 (en) Compounds
ZA201605726B (en) Novel compounds
GB201421834D0 (en) Novel compounds
GB201421784D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)